Uterine Fibroid Treatment - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Medical Care > Uterine Fibroid Treatment - Global Top Players Market Share and Ranking 2025

Uterine Fibroid Treatment - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-11-13
Report Id: 2765159
Industry: Medical Care
Report Page: 92
Chart: 99

PDF Download

Publication Date: 2025-11-13
Report Id: 2765159
Industry: Medical Care
Report Page: 92
Chart: 99

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Uterine Fibroid Treatment Definition
1.2 Global Uterine Fibroid Treatment Market Size and Forecast
1.3 China Uterine Fibroid Treatment Market Size and Forecast
1.4 Share of China Uterine Fibroid Treatment Market with Respect to the Global Market
1.5 Uterine Fibroid Treatment Market Size: China VS Global Growth Rate, 2020-2031
1.6 Uterine Fibroid Treatment Market Dynamics
1.6.1 Uterine Fibroid Treatment Market Drivers
1.6.2 Uterine Fibroid Treatment Market Restraints
1.6.3 Uterine Fibroid Treatment Industry Trends
1.6.4 Uterine Fibroid Treatment Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Uterine Fibroid Treatment, Global Market Share by Company, 2020-2025
2.2 Global Uterine Fibroid Treatment Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Uterine Fibroid Treatment Concentration Ratio
2.4 Global Uterine Fibroid Treatment Mergers & Acquisitions, Expansion Plans
2.5 Global Uterine Fibroid Treatment Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Uterine Fibroid Treatment, China Market Share by Company, 2020-2025
3.2 China Uterine Fibroid Treatment Uterine Fibroid Treatment Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Uterine Fibroid Treatment Industry Chain
4.2 Uterine Fibroid Treatment Upstream Analysis
4.2.1 Uterine Fibroid Treatment Core Raw Materials
4.2.2 Main Manufacturers of Uterine Fibroid Treatment Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Uterine Fibroid Treatment Production Mode
4.6 Uterine Fibroid Treatment Procurement Model
4.7 Uterine Fibroid Treatment Industry Sales Model and Sales Channels
4.7.1 Uterine Fibroid Treatment Sales Model
4.7.2 Uterine Fibroid Treatment Typical Distributors

5 Sights by Type
5.1 Uterine Fibroid Treatment Classification by Type
5.1.1 Operation Treatment
5.1.2 Ablation Technique
5.1.3 Embolization Technique
5.2 by Type, Global Uterine Fibroid Treatment Consumption Value & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Uterine Fibroid Treatment Consumption Value, 2020-2031

6 Sights by Treatment Modality
6.1 Uterine Fibroid Treatment Classification by Treatment Modality
6.1.1 Minimally Invasive Procedures
6.1.2 Surgical Therapy
6.1.3 Other
6.2 by Treatment Modality, Global Uterine Fibroid Treatment Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Treatment Modality, Global Uterine Fibroid Treatment Consumption Value, 2020-2031

7 Sights by Technological Approach
7.1 Uterine Fibroid Treatment Classification by Technological Approach
7.1.1 Image-Guided Therapy
7.1.2 Robotic-Assisted Surgery
7.1.3 Other
7.2 by Technological Approach, Global Uterine Fibroid Treatment Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Technological Approach, Global Uterine Fibroid Treatment Consumption Value, 2020-2031

8 Sights by End Use
8.1 Uterine Fibroid Treatment Segment by End Use
8.1.1 Public Hospital
8.1.2 Private Hospital
8.2 by End Use, Global Uterine Fibroid Treatment Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by End Use, Global Uterine Fibroid Treatment Consumption Value, 2020-2031

9 Sales Sights by Region
9.1 By Region, Global Uterine Fibroid Treatment Consumption Value, 2020 VS 2024 VS 2031
9.2 By Region, Global Uterine Fibroid Treatment Consumption Value, 2020-2031
9.3 North America
9.3.1 North America Uterine Fibroid Treatment Market Size & Forecasts, 2020-2031
9.3.2 By Country, North America Uterine Fibroid Treatment Market Size Market Share
9.4 Europe
9.4.1 Europe Uterine Fibroid Treatment Market Size & Forecasts, 2020-2031
9.4.2 By Country, Europe Uterine Fibroid Treatment Market Size Market Share
9.5 Asia Pacific
9.5.1 Asia Pacific Uterine Fibroid Treatment Market Size & Forecasts, 2020-2031
9.5.2 By Country/Region, Asia Pacific Uterine Fibroid Treatment Market Size Market Share
9.6 South America
9.6.1 South AmericaUterine Fibroid Treatment Market Size & Forecasts, 2020-2031
9.6.2 By Country, South America Uterine Fibroid Treatment Market Size Market Share
9.7 Middle East & Africa

10 Sales Sights by Country Level
10.1 By Country, Global Uterine Fibroid Treatment Market Size & CAGR, 2020 VS 2024 VS 2031
10.2 By Country, Global Uterine Fibroid Treatment Consumption Value, 2020-2031
10.3 United States
10.3.1 United States Uterine Fibroid Treatment Market Size, 2020-2031
10.3.2 by Type, United States Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.3.3 by End Use, United States Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.4 Europe
10.4.1 Europe Uterine Fibroid Treatment Market Size, 2020-2031
10.4.2 by Type, Europe Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.4.3 by End Use, Europe Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.5 China
10.5.1 China Uterine Fibroid Treatment Market Size, 2020-2031
10.5.2 by Type, China Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.5.3 by End Use, China Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.6 Japan
10.6.1 Japan Uterine Fibroid Treatment Market Size, 2020-2031
10.6.2 by Type, Japan Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.6.3 by End Use, Japan Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.7 South Korea
10.7.1 South Korea Uterine Fibroid Treatment Market Size, 2020-2031
10.7.2 by Type, South Korea Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.7.3 by End Use, South Korea Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.8 Southeast Asia
10.8.1 Southeast Asia Uterine Fibroid Treatment Market Size, 2020-2031
10.8.2 by Type, Southeast Asia Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.8.3 by End Use, Southeast Asia Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.9 India
10.9.1 India Uterine Fibroid Treatment Market Size, 2020-2031
10.9.2 by Type, India Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.9.3 by End Use, India Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.10 Middle East & Africa
10.10.1 Middle East & Africa Uterine Fibroid Treatment Market Size, 2020-2031
10.10.2 by Type, Middle East & Africa Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031
10.10.3 by End Use, Middle East & Africa Uterine Fibroid Treatment Consumption Value Market Share, 2024 VS 2031

11 Company Profile
11.1 Boston Scientific
11.1.1 Boston Scientific Company Information, Head Office, Market Area, and Industry Position
11.1.2 Boston Scientific Company Profile and Main Business
11.1.3 Boston Scientific Uterine Fibroid Treatment Models, Specifications, and Application
11.1.4 Boston Scientific Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.1.5 Boston Scientific Recent Developments
11.2 CooperSurgical
11.2.1 CooperSurgical Company Information, Head Office, Market Area, and Industry Position
11.2.2 CooperSurgical Company Profile and Main Business
11.2.3 CooperSurgical Uterine Fibroid Treatment Models, Specifications, and Application
11.2.4 CooperSurgical Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.2.5 CooperSurgical Recent Developments
11.3 Karl Storz
11.3.1 Karl Storz Company Information, Head Office, Market Area, and Industry Position
11.3.2 Karl Storz Company Profile and Main Business
11.3.3 Karl Storz Uterine Fibroid Treatment Models, Specifications, and Application
11.3.4 Karl Storz Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.3.5 Karl Storz Recent Developments
11.4 Merit Medical
11.4.1 Merit Medical Company Information, Head Office, Market Area, and Industry Position
11.4.2 Merit Medical Company Profile and Main Business
11.4.3 Merit Medical Uterine Fibroid Treatment Models, Specifications, and Application
11.4.4 Merit Medical Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.4.5 Merit Medical Recent Developments
11.5 Olympus
11.5.1 Olympus Company Information, Head Office, Market Area, and Industry Position
11.5.2 Olympus Company Profile and Main Business
11.5.3 Olympus Uterine Fibroid Treatment Models, Specifications, and Application
11.5.4 Olympus Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.5.5 Olympus Recent Developments
11.6 Richard Wolf
11.6.1 Richard Wolf Company Information, Head Office, Market Area, and Industry Position
11.6.2 Richard Wolf Company Profile and Main Business
11.6.3 Richard Wolf Uterine Fibroid Treatment Models, Specifications, and Application
11.6.4 Richard Wolf Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.6.5 Richard Wolf Recent Developments
11.7 Chongqing Haifu
11.7.1 Chongqing Haifu Company Information, Head Office, Market Area, and Industry Position
11.7.2 Chongqing Haifu Company Profile and Main Business
11.7.3 Chongqing Haifu Uterine Fibroid Treatment Models, Specifications, and Application
11.7.4 Chongqing Haifu Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.7.5 Chongqing Haifu Recent Developments
11.8 Haiying
11.8.1 Haiying Company Information, Head Office, Market Area, and Industry Position
11.8.2 Haiying Company Profile and Main Business
11.8.3 Haiying Uterine Fibroid Treatment Models, Specifications, and Application
11.8.4 Haiying Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.8.5 Haiying Recent Developments
11.9 Puluo Medical
11.9.1 Puluo Medical Company Information, Head Office, Market Area, and Industry Position
11.9.2 Puluo Medical Company Profile and Main Business
11.9.3 Puluo Medical Uterine Fibroid Treatment Models, Specifications, and Application
11.9.4 Puluo Medical Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.9.5 Puluo Medical Recent Developments
11.10 Shanghai A&S
11.10.1 Shanghai A&S Company Information, Head Office, Market Area, and Industry Position
11.10.2 Shanghai A&S Company Profile and Main Business
11.10.3 Shanghai A&S Uterine Fibroid Treatment Models, Specifications, and Application
11.10.4 Shanghai A&S Uterine Fibroid Treatment Revenue and Gross Margin, 2020-2025
11.10.5 Shanghai A&S Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for Uterine Fibroid Treatment should grow from US$ 3323 million in 2024 to US$ 4666 million by 2031, with a CAGR of 5.0% for the period of 2025-2031.

Uterine fibroid treatment refers to a range of medical interventions targeting benign smooth muscle tumors of the uterus, including pharmacological therapies, interventional procedures, minimally invasive surgeries, and traditional open surgeries. These treatments aim to alleviate symptoms such as heavy menstrual bleeding, pelvic pain, and infertility, while preserving uterine function whenever possible. With the advancement of minimally invasive techniques, imaging-guided technologies, and novel therapeutics, uterine fibroid treatments are evolving toward personalized, precise, and low-risk approaches to meet diverse patient needs and improve quality of life.The average gross profit margin of this product is 60%.

Uterine Fibroid Treatment

According to YH Research, the global market for Uterine Fibroid Treatment should grow from US$ 3323 million in 2024 to US$ 4666 million by 2031, with a CAGR of 5.0% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The uterine fibroid treatment market is driven by multiple factors. Growing female populations and delayed childbirth trends increase the prevalence of uterine fibroids, expanding the patient base. Advancements in minimally invasive and non-invasive procedures reduce surgical risks and enhance patient acceptance. Broader insurance coverage and increased health awareness stimulate early diagnosis and treatment demand. Furthermore, the application of imaging-guided technologies and novel drugs improves treatment precision and efficacy, providing continuous innovation momentum for the market.

The industry faces several challenges and risks. Uneven distribution of medical resources across regions leads to disparities in access to high-quality treatments. High costs of some novel drugs and devices affect accessibility and adoption. Additionally, potential complications and recurrence risks during treatment increase the overall medical burden. Regulatory variations, clinical guidelines, and approval processes also pose constraints on the adoption of new technologies and therapeutics.

Demand from patients and healthcare providers is moving toward personalized and ref ined uterine fibroid treatment. Minimally invasive surgeries and combined pharmacological approaches are preferred among younger patients, while non-surgical and imaging-guided interventions are becoming mainstream. Increased awareness of early screening and health management drives patient focus on efficacy, safety, and post-treatment recovery, fueling demand for advanced treatment options and smart medical devices.

The upstream supply for uterine fibroid treatment includes imaging device components, minimally invasive surgical instruments, medical-grade materials, and active pharmaceutical ingredients. High-precision imaging sensors and catheter-based instruments determine the accuracy of minimally invasive treatments. Medical-grade plastics and metals ensure device safety and durability. Active drug ingredients and formulation technologies directly impact therapeutic efficacy. Smart surgical navigation and remote monitoring systems provide technical support for emerging treatment approaches. With material innovation and supply chain optimization, stability and quality of upstream resources are critical for industry growth.

This report studies and analyses global Uterine Fibroid Treatment status and future trends, to help determine the Uterine Fibroid Treatment market size of the total market opportunity by Type, by End Use, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Uterine Fibroid Treatment, and provides market size (US$ million) and Year-over-Year growth, considering 2023 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Uterine Fibroid Treatment market size, history data 2019-2024, and forecast data 2025 -2030, (US$ million)
(2) Global Uterine Fibroid Treatment by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(3) China Uterine Fibroid Treatment by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(4) Global Uterine Fibroid Treatment key consuming regions, consumption value and demand structure
(5) Uterine Fibroid Treatment industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Boston Scientific
CooperSurgical
Karl Storz
Merit Medical
Olympus
Richard Wolf
Chongqing Haifu
Haiying
Puluo Medical
Shanghai A&S

Market segment by Type, covers
Operation Treatment
Ablation Technique
Embolization Technique

Market segment by End Use, can be divided into
Public Hospital
Private Hospital

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Uterine Fibroid Treatment product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Uterine Fibroid Treatment market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 3: China Uterine Fibroid Treatment market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 4: Uterine Fibroid Treatment industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2019-2030
Chapter 6: Segment by End Use, consumption value, percent & CAGR, 2019-2030
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2019-2030
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2019-2030
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions